Time course of release of inflammatory markers after coronary stenting: Comparison between bare metal stent and sirolimus-eluting stent

Coronary Artery Disease

Volumn 16, Issue 8, 2005, Pages 505-509

  Kefer, Joëlle M ^a,b   Galanti, Laurence M ^a   Desmet, Sandrine ^a   Deneys, Véronique ^a   Hanet, Claude E ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Coronary angioplasty; Drug eluting stent; Inflammation; Restenosis; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; RAPAMYCIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY SINUS; CORONARY STENT; CYTOKINE RELEASE; DEMOGRAPHY; DRUG ELUTING STENT; FEMALE; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTIGENS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-6; MALE; METALS; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; SINUS OF VALSALVA; SIROLIMUS; STENTS; TROPONIN I; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 33748528916     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200512000-00009     Document Type: Article

References (19)

1. Liuzzo G, Buffon A, Biasucci LM, Gallimore J, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 22:2370-2380.
2. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001; 24:701-714.
3. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of Interleukin-6 in unstable angina. Circulation 1996; 94:874-877.
4. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39:1917-1923.
5. Spaziani D, De Servi S, Morelli B, D'Urbano M, Vandoni P, Mariani G, et al. Different patterns of interleukin-6 and von Willebrand factor antigen changes after coronary stenting in unstable versus stable angina. Ital Heart J 2002; 3:593-597.
6. Ridker P. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813-1818.
7. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti T, Ramazzoti V, Rebuzzi A, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34:1512-1521.
8. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki H, et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84:83-87.
9. Kefer J, Galanti L, Hanet C. Time course of transcardiac interleukin-6 release after coronary stenting for stable angina. Heart 2004; 90:943-944.
10. Gorog D, Douglas H, Ahmed N, Lefroy D, Davies G. Coronary angioplasty enhances platelet reactivity through von Willebrand factor release. Heart 2003; 89:329-330.
11. Suzuki T, Kopia G, Hayashi S, Bailey L, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104:1188-1193.
12. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting stent Bx velocity balloon-expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106:1949-1956.
13. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa J, Colombo A, et al. Intravascular ultrasound findings of the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002; 106:798-803.
14. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
15. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995; 92:31-38.
16. Yazdani S, Simon A, Kovar L, Wang W, Schwartz A, Rabbani L, et al. Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina. J Am Coll Cardiol 1997; 30:1284-1287.
17. Nitu-Whalley C, Lee C, Brown S, Riddell A, Hermans C. The role of the platelet function analyser (PFA-100 TM) in the characterization of patients with von Willebrand's disease and it's relationships with von Willebrand factor and the ABO blood group. Haemophilia 2003; 9:298-302.
18. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard J, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Circulation 1998; 98:294-299.
19. Visner G, Lu F, Zhou H, Liu J, Kazemfar K, Agarwal A. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells. Circulation 2003; 107:911-916.